Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

NGX426 as treatments for migraine and other indications,. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine, neuropathic pain and/or other indications for which they are developed, or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are b
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... April 22 Sysmex America, Inc. today,announced ... (Canton, OH),beta studies for its integrated hematology ... combines the Sysmex HST-N hematology,automation platform and ... enables on-demand, automated diabetes testing in a ...
... Ga., April 22 Identity Sciences, LLC (IDS),with ... (INL), has,developed a new forensic human identification test, ... hours. AbP ID does not use DNA;,instead, it ... all human body tissues and fluids. Each individual,including ...
... ... Markets, WILMINGTON, Del., April 22 , Highlights -- ... the prior year. Excluding a significant item charge in the prior year, ... $8.6 billion, reflecting 6 percent higher local selling prices and 5 ...
Cached Biology Technology:Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 3Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 4Identity Sciences Introduces a New, Fast Forensic Human I.D. Test 2DuPont Reports First Quarter Earnings Growth of Over 20 Percent 2DuPont Reports First Quarter Earnings Growth of Over 20 Percent 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 4DuPont Reports First Quarter Earnings Growth of Over 20 Percent 5DuPont Reports First Quarter Earnings Growth of Over 20 Percent 6DuPont Reports First Quarter Earnings Growth of Over 20 Percent 7DuPont Reports First Quarter Earnings Growth of Over 20 Percent 8DuPont Reports First Quarter Earnings Growth of Over 20 Percent 9DuPont Reports First Quarter Earnings Growth of Over 20 Percent 10DuPont Reports First Quarter Earnings Growth of Over 20 Percent 11DuPont Reports First Quarter Earnings Growth of Over 20 Percent 12DuPont Reports First Quarter Earnings Growth of Over 20 Percent 13DuPont Reports First Quarter Earnings Growth of Over 20 Percent 14DuPont Reports First Quarter Earnings Growth of Over 20 Percent 15DuPont Reports First Quarter Earnings Growth of Over 20 Percent 16DuPont Reports First Quarter Earnings Growth of Over 20 Percent 17DuPont Reports First Quarter Earnings Growth of Over 20 Percent 18
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... for Genomics and Systems Biology (IGSB), a joint venture of ... the University of Chicago, has acquired two new instruments that ... broadly. "Sequencing used to be like locating a ... the rough," said IGSB Director Kevin White. "It used to ...
... Spanish . Networks for radiological ... the environment and detect possible incidents. The PhD ... at the University of the Basque Country provides ... and radiological incidents caused externally. Most ...
... of having male or female offspring. Research published today ... Endocrinology has demonstrated that ewes fed a diet enriched ... have a significantly higher chance of giving birth to ... a team of researchers from the Division of Animal ...
Cached Biology News:Argonne-University of Chicago joint venture bolsters genomic sequencing capabilities 2More sensitive radiology monitoring in the Basque Country 2More sensitive radiology monitoring in the Basque Country 3Diet prior to pregnancy determines sheep's gender 2
9 D10...
chk 1 kinase...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: